Response to comment on ‘Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial’

被引：0
|
作者：
M L Subramanian
机构：
[1] Boston University School of Medicine and the VA Boston Healthcare System,Department of Ophthalmology
来源：
Eye | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：820 / 820
相关论文
共 50 条
  • [1] Response to comment on 'Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial'
    Wakefield, M. J.
    Tole, D. M.
    Bailey, C. C.
    Mundasad, M. V.
    Sparrow, J. M.
    EYE, 2011, 25 (06) : 821 - 821
  • [2] Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial
    Subramanian, M. L.
    Abedi, G.
    Ness, S.
    Ahmed, E.
    Fenberg, M.
    Daly, M. K.
    Houranieh, A.
    Feinberg, E. B.
    EYE, 2010, 24 (11) : 1708 - 1715
  • [3] Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial
    M L Subramanian
    G Abedi
    S Ness
    E Ahmed
    M Fenberg
    M K Daly
    A Houranieh
    E B Feinberg
    Eye, 2010, 24 : 1708 - 1715
  • [4] Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
    Subramanian, Manju L.
    Ness, Steven
    Abedi, Gelareh
    Ahmed, Ednan
    Daly, Mary
    Feinberg, Edward
    Bhatia, Sumit
    Patel, Payal
    Nguyen, Maileah
    Houranieh, Antoun
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (06) : 875 - 882
  • [5] Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial REPLY
    Subramanian, Manju
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 150 (02) : 287 - 287
  • [6] A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
    Krebs, Ilse
    Schmetterer, Leopold
    Boltz, Agnes
    Told, Reinhard
    Vecsei-Marlovits, Veronika
    Egger, Stefan
    Schoenherr, Ulrich
    Haas, Anton
    Ansari-Shahrezaei, Siamak
    Binder, Susanne
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (03) : 266 - 271
  • [7] Bevacizumab vs Ranibizumab: One Year Outcomes of a Head to Head, Prospective, Double-Masked, Randomized Clinical Trial
    Subramanian, M. L.
    Abedi, G.
    Ness, S.
    Feinberg, E. B.
    Fenberg, M. J.
    Daly, M.
    Houranieh, A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [8] Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
    Regillo, Carl D.
    Brown, David M.
    Abraham, Prema
    Yue, Huibin
    Ianchulev, Tsontcho
    Schneider, Susan
    Shams, Naveed
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (02) : 239 - 248
  • [9] Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study
    Ghazi, Nicola G.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2010, 3 (06) : 747 - 752
  • [10] A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
    J H Vallance
    B Johnson
    M A Majid
    S Banerjee
    K Mandal
    C C Bailey
    Eye, 2010, 24 : 1561 - 1567
12345